

- 14 -

AMENDED CLAIMS

[received by the International Bureau on 5 August 1997 (05.08.97);
original claims 1-24 replaced by amended claims 1-24 (3 pages)]

1. The use of an inhibitor of IFN- γ in the manufacture of a medicament for promoting the healing of wounds or fibrotic disorders with reduced scarring.
2. The use of an inhibitor of IFN- γ according to claim 1, the inhibitor comprising a neutralising antibody.
3. The use of an inhibitor of IFN- γ according to either one of claims 1 or 2, the inhibitor being selected from any one of the group of a monoclonal antibody, a polyclonal antibody, a phage-derived antibody, a genetically engineered antibody and an antibody derived from a transgenic mouse.
4. The use of an inhibitor of IFN- γ according to any one of claims 1-3 wherein the inhibitor prevents IFN- γ interacting with its receptor.
5. The use of an inhibitor of IFN- γ according to any one of the preceding claims for use in conjunction with a pharmaceutically acceptable carrier, diluent or excipient.
6. The use of an inhibitor of IFN- γ according to any one of the preceding claims for use in conjunction with a composition for promoting the healing of wounds or fibrotic disorders with reduced scarring.
7. The use of an inhibitor of IFN- γ according to any one of the preceding claims for use in conjunction with a composition for promoting the healing of chronic wounds.

- 15 -

8. A method for promoting the healing of wounds or fibrotic disorders with reduced scarring comprising the use of an inhibitor of IFN- γ according to any one of the preceding claims.
9. A method according to claim 8, comprising administering to a site of wounding or fibrosis an inhibitor of IFN- γ .
10. A method according to any one of claims 8-9, comprising inhibiting between about 300 and about 30,000 IU IFN- γ .
11. A method according to any one of claims 8-10, IFN- γ being inhibited either immediately prior to wounding/onset or immediately after wounding/onset.
12. A method according to any one of claims 8-11 used in conjunction with a method for promoting the healing of wounds or fibrotic disorders with reduced scarring.
13. A method according to any one of claims 8-12 used in conjunction with a method for promoting the healing of chronic wounds.
14. The use of a stimulator of IFN- γ in the manufacture of a medicament for promoting the healing of chronic wounds.
15. The use of a stimulator of IFN- γ according to claim 15 wherein it is selected from any one of the group of IFN- γ or a partially modified form thereof, and an inhibitor of IFN- γ metabolism.
16. The use of a stimulator of IFN- γ according to either one of claims 14 or 15 in conjunction with a pharmaceutically acceptable carrier, diluent or excipient.

17. The use of a stimulator of IFN- γ according to any one of claims 15-17 in conjunction with a composition for promoting the healing of wounds or fibrotic disorders with reduced scarring.
18. The use of a simulator of IFN- γ according to any one of claims 15-18 in conjunction with a composition for promoting the healing of chronic wounds.
19. A method for promoting the healing of chronic wounds comprising the use of a stimulator of IFN- γ according to any one of claims 14-18.
20. A method according to claim 19, comprising administering to a site of wounding a stimulator of IFN- γ .
21. A method according to either one of claims 19 or 20 comprising the use of between about 7,500 and 15,000 IU IFN- γ .
22. A method according to any one of claims 19-21, comprising stimulating IFN- γ either immediately prior to wounding or immediately after wounding.
23. A method according to any one of claims 19-22 used in conjunction with a method for promoting the healing of wounds or fibrotic disorders with reduced scarring.
24. A method according to any one of claims 19-23 used in conjunction with a method for promoting the healing of chronic wounds.